ASX-listed PharmAust subsidiary, Epichem, has entered into a multi-year license agreement to harness “Oxidative Hydrothermal Dissolution” technology from IP owner, Illinois-based Thermaquatica. Epichem will research, develop and promote Thermaquatica's disruptive waste to fuels technology that uses waste and biomass as a feedstock. The company will also target government grant funding to accelerate its research and development initiative.
